Affinity chromatography and reverse-phase high-performance liquid chromatography was used to purify a soluble interleukin lfl (Ib13) specific binding protein from the supernatant of a human B cell line, Raji. The purified protein specifically bound 12sI IL-lfl forming a 60-kD complex in nonreducing conditions and a 70-kD complex in reducing conditions. Binding was found to be displaceable by mature human and murine IL-lfl and human 31-kD ILlfl propeptide, but not displaceable by human and murine II. 
I blc~ and IL-lfl are polypeptides with central roles in the regulation of immune and inflammatory reactions (1) . ILl responses are mediated by specific high affinity cell surface receptors (II~IR) of which at least two distinct forms are known to exist (2) . An 80-kD (type I) receptor is found mainly on T cells and fibroblasts (3) , and a lower molecular mass 65-kD, (type II) receptor is found on B cells (4) and macrophages. Many cytokine receptors are known to exist in soluble form, and release from the cell surface occurs by two distinct mechanisms. Alternative splicing of the primary RNA transcript can result in protein isoforms that lack transmembrane domains and are therefore secreted, e.g., IL-4R (5) . Proteolytic cleavage of the transmembrane molecule at the cell surface, e.g., IL2R (p55) (6) , also results in receptor shedding. Other cytokine receptors that exist in soluble form include those for IL-2 (p75) IL-5, II~6, IL-7, IFN-'y, TNF (p75 and p55), epidermal growth factor (EGF), and M-CSF.
We have recently described a sohble binding protein specific for IL-lfl present in normal human plasma (7), serum, synovial inflammatory exudate, activated PBMC supernatants (8) , and supernatants from the human B cell line, Raji (9) . Stimulation of Raji with dexamethasone increased surface expression of the ID1R and the rate of release of soluble binding protein. Conversely, a serine protease inhibitor prevented release of the binding protein and increased IL-1R expression of the cells. Together, the data indicate that the soluble IL-lfl binding protein is probably a proteolyticaUy cleaved form of a surface IL1R. Here we report the purification and characterization of this novel soluble (s)IL-1R and provide evidence that it may function as a naturally occurring regadator of IL-lfl.
Materials and Methods
Purification ofRaji slL.1g. The Raji cell line was obtained from the European Cell Culture Collection (Porton, Wilts, UK). Ceils were maintained at 37~ in RPMI 1640 containing 5% FCS, and media was aspirated every 3-4 d, centrifuged, and stored at -50~ Before purification, cukure supernatants were concentrated 20-fold using a Minitan ultra filtration system containing 10-kD cut-off filters (MiUipore Continental Water Systems, Bedford, MA). slblR protein was detected by soluble covalent crosslinking as previously described (8) .
Partial purification of the sIblR was achieved using a wheatgerm agglutinin sepharose 6MB column (Pharmacia LKB Biotechnology, UK) as previously described, sIblR was further purified using a IL-lfl (mutant K138C) (10) thiol sepharose column containing 4 mg/ml Iblfl. Concentrated Iblfl binding protein preparations were applied to the column using a flow rate of 1 ml/min and continually recycled for up to 48 h at 4~ The column was then washed in 100 mM Tris-HC1, pH 8.1 (20-column volumes), 100 mM Tris-HC1, pH 8.1, 1.0 M NaC1 (20-column volumes), and subsequently eluted with 5 ml of 3 M NH4SCN in PBS. The eluate was extensively dialyzed against 100 mM Tris-HC1, pH 8.1, concentrated 10-fold with a centripep concentrator (cut-off, 10 kD; Amicon Ltd.) and stored at -70~ Affinity-purified, sIL-1R, was injected onto a reverse-phase, RP300 Aquapore 30 x 2.1-mm C8 column (Applied Biosystems Inc., Foster City, CA). Sample was eluted in a 10-70% (vol/vol) acetonitrile gradient with 0.3% (vol/vol) trifluoroacetic acid over a 45-min period at a flow rate of 0.2 ml/min. After neutralization with Tris, fractions were screened for IL-1 binding activity by soluble covalent crosslinking.
Ligand Blotting ofslL-1g. Purified sIL-1R. (5/zl) was subjected to electrophoresis on 10% SDS-polyacrylamide gels and trans- Soluble and Cell Su~ce 12s111,1 Binding Assay. Soluble binding assays with purified slL-1R and cell surface binding assays using 5 x 106 cells were performed as previously described (8) .
Inhibition of Cell Surface 11,1 Binding by slL1R. Raji and Eb4
NOB.1 cells (107) were incubated with 5 ng/ml 12sI Iblc~ or 12sI IL-lfl with or without decreasing concentrations of purified sIb 1R at 4~ for 3 h with constant agitation. Cell surface 12sI Ibl binding was assessed as before.
Results

Purification ofRaji slL-IR. Wheat germ agglutinin and
Ibl/~ affinity-purified, soluble II.-1R was injected onto a reverse-phase HPLC column, sIL-1R eluted with ~43% (vol/vol) acetonitrile as determined by soluble crosslinking and was associated with three overlapping protein peaks (data not shown). Ligand Blotting of slL-13 Binding Protein. Purified slblR was separated on a 10% SDS-PAGE gel under nonreducing conditions and blotted onto nitrocellulose. Probing with 12sI IL-13 revealed a band migrating at 47 kD (Fig. 2) . This band was also seen when the blots were incubated with 100-fold excess cold ILlot or TNF-ot but not when incubated with excess cold II:1/3. No binding was seen when the slL-1R was separated under reducing conditions (data not shown). Cell Surface and Soluble Raft II~IR Binding. Analysis of 12sI I1:1/5 binding to the Raji cell surface IL-1K and sllclK showed that both exhibited specific and saturable binding (Fig.  3) . Scatchard analysis revealed that the Raji cell surface I1:1K bound lz5I I1:1/5 with an apparent Kd of 2.2 nM (Fig. 3 A) , while the soluble receptor protein bound 12sI I1:1/5 with a Ka of 2.7 nM (Fig. 3 B) .
Specificity of slL,1R Ligand
Inhibition of lLIR Binding by slIMR. Raji (type II I1:1R
bearing) and EL-4 NOB.1 (type I IL-1K bearing) cells were incubated with nsI I1:1ot and nsI I1:1/5 in the presence or absence of decreasing concentrations of purified sI1:lR (Fig.  4) . Raji did not bind 12sI I1:1c~ (data not shown), however, nsI IL-1/5 binding was inhibited in a dose-related fashion by the sI1:lK preparation. The sI1:lR also inhibited nsI I1:1/5 binding to the E1:4 NOB.1 cell line, however, nsI I1:1c~ binding was not affected by incubation with sI1:lR.
Discussion
The present study described the purification and characterization of a sIL-1R derived from the supernatant of the human B cell Burkitt lymphoma cell line Raft. The protein binds Ibl/5 but not Iblo~. We have previously described a protein with the same properties in normal human plasma, serum, synovial exudate, and supernatants from activated PBMC (7, 8) .
We purified the Raji sI1:lR by sequential wheat germ agglutinin affinity chromatography, Ibl/5 affinity chromatography, and reverse-phase HPLC. The specificity of this material was characterized by using soluble covalent crosslinking and confirmed our previous findings that the sILLR specificaUy bound to IL-1/5. Murine IL-1 molecules showed the same binding specifidty to the purified slL-1R. The human IblR antagonist (12) failed to inhibit binding of lzsI IL-1/5 to the slI~lR, and it has been reported that this molecule fails to bind the type II cell surface I1:IR. Interestingly, we found that excess human 31-kD IL-1/5 propeptide could displace the mature 17-kD molecule from the sIDIR. Previously published studies have shown that the IL-1B propeptide fails to bind the type I I1:1R and has no biological activity on cells with this receptor (13) . The finding that the sIblR binds to the propeptide may have important implications for the in vivo handiing of Ibl/5. Treatment of the sIL-1R/nSI I1:1/5 complex with reducing agents revealed an apparent change in the molecular mass of the complex from ,,060 to '~70 kD. As I1:1/5 contains no disulphide linkages, it is likely that the sIL-1R is held in its conformational shape by disulphide bonds. Further characterization of the sIblR was achieved by ligand blotting, previously used to study a number of cell surface receptors, including the type I IblR (11) . Ligand blotting demonstrated a 47-kD molecule in nonreducing conditions that, again, specifically bound Ibl/5. Use of reducing agents led to loss of binding activity (data not shown), indicating that the disulphide-bonded cysteine residues probably hold the receptor in a functional conformation.
Scatchard analysis of cell surface and soluble l~sI IL1/5 binding showed the Ka of the cell surface IblR to be 2.2 riM. This is in good agreement with previous studies (14) . We have previously demonstrated that a sIbl/5 binding protein semi-purified from synovial fluid (SF) had a Ka of *0.4 nM (8) . Analysis of the binding of IL-1/5 to the Raji sIblR revealed a Kd of 2.7 nM very similar to the Raji cell surface IblR, although others have found Raji sI1:lR to have a lower affinity (15) . The sixfold difference in the affinity of the SF sI1:lR and the Raji-derived sI1:lR might be explained by other Ibl binding factors in the SF preparations. However, pancreatic islet/5 cells also possess I1:IR specific for Ibl/5 and appear to express both high (Kd = 0.2 riM) and low (Ka = 1.4 nM) sites (16) , therefore synovial cells may shed a higher affinity sIblR than the Raji done.
Given the high affinity for ILd/5, the molecule may function as a specific inhibitor of I1:1/5 in vivo. To test this, we performed binding studies using EL-4 NOB.l, a T cell line with a type I IblR, and Raji cells that only possess a type II ID1R. The results showed that the sIblR inhibited IL-1/5 binding to both cell lines in a dose-dependent fashion, however, Iblot binding to E1:4 NOB.1 was not inhibited. Soluble cytokine receptors may have considerable therapeutic potential. Recent studies have used a recombinant truncated type I I1:IR to inhibit rejection of heart aUografts (17) and I1:1 induced B cell function (18) . The natural soluble IL1R may play an important role in modulating I1:1/5 activities in vivo.
The finding of certain cell types able to discriminate between IL-lc~ and I1:1/5 has important biological implications. It has been noted that I1:1/5 is more potent than Iblol in the brain, pancreas, ovarian granulosa cells, leydig cells, and immunostimulatory activity in vivo. Differential expression of IL-1R types may explain these observations. Additionally release of the sI1:lR could be induced from normal human
